Document is current
Any future updates will be listed below
-
Authors
Stolte, Benjamin https://orcid.org/0000-0002-2774-067X
Nonnemacher, Michael https://orcid.org/0000-0003-1317-6120
Kizina, Kathrin
Bolz, Saskia https://orcid.org/0000-0003-1209-1715
Totzeck, Andreas
Thimm, Andreas https://orcid.org/0000-0002-7806-9919
Wagner, Bernd https://orcid.org/0000-0003-0877-6906
Deuschl, Cornelius https://orcid.org/0000-0001-9262-7289
Kleinschnitz, Christoph https://orcid.org/0000-0002-1650-8875
Hagenacker, Tim https://orcid.org/0000-0002-3631-3450
-
Funding
Funding for this research was provided by:
Universität Duisburg-Essen
- License Information
-
More Information
Article History
Received: 2 March 2021
Revised: 15 April 2021
Accepted: 16 April 2021
First Online: 25 April 2021
Declarations
:
: BS received travel reimbursement and speaker honoraria from Biogen. MN declared no conflicts of interest. KK received travel reimbursement and speaker honoraria from Biogen. SB declared no conflicts of interest. ATo declared no conflicts of interest. ATh received travel reimbursement from CSL Behring. BW declared no conflicts of interest. CD declared no conflicts of interest. CK received honoraria from Biogen and Roche. TH received honoraria from Novartis, Roche and Biogen and research support from Biogen, Roche and AveXis.
: The study was approved by the Ethics Committee of the University Duisburg-Essen, Germany (approval number: 18-8071-BO) and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Written informed consent was obtained from every patient included in this study.
